GMRS reports its first earnings as a public company today with the stock trading at $12.86 — up 8% on Wednesday alone, though still down 17% over the past month.
Short selling activity carries an unusual footnote ahead of this print. Estimated short shares jumped roughly 70% in a single session on August 11, a sharp spike that looks more like a positioning adjustment around the debut print than a conviction bearish build. Crucially, the borrow market tells a completely different story: availability is extremely loose at 1,357% — meaning there are more than thirteen shares available to borrow for every one already lent out. That dwarfs the 52-week tightest reading of 240%. Cost to borrow has fallen by half over the past month to just 2.3%. This is not a squeezed or contested lending market by any measure, and the short-interest spike should be read in that context.
The analyst community entered this print broadly constructive. A cluster of initiations landed on June 8 from Goldman Sachs (Buy, $35 target), BofA (Buy, $18), UBS (Buy, $20), Evercore ISI (Outperform, $20), and Citigroup (Buy, $17), alongside Morgan Stanley at Equal-Weight with a $14 target and JPMorgan and Barclays at Overweight. The consensus mean target is $19.38, implying around 50% upside from the current price — though the Goldman $35 target is a notable outlier relative to the pack. That wide dispersion on targets reflects genuine uncertainty rather than analyst alignment: the Street agrees the direction is up, but disagrees sharply on how far. With all of these initiations coming in June and no updates since, the print today is the first real test of those initial theses.
Valuation is modest on trailing numbers. The stock trades at roughly 7.4x trailing earnings and 4.8x EV/EBITDA — both well below typical healthcare services multiples — which gives the bull case a straightforward entry point argument. Bears, anchored by the Morgan Stanley Equal-Weight at $14, are essentially at the current price, suggesting limited downside cushion is already priced in at current levels. KKR holds 19% of shares and Koch Equity Development another 2.8%, meaning the ownership structure is concentrated and institutional — a backdrop that tends to limit disorderly selling but also limits the float available for any short-covering dynamic.
The earnings history carries one sharp data point: a 15% single-day decline in early June, followed by a roughly 6% drop at the formal June 2 report date, with a near-flat five-day recovery. Today's print will test whether the company can demonstrate the revenue trajectory and margin profile that would pull analyst targets toward the $19–$20 range — and away from the $14 floor that Morgan Stanley set.
See the live data behind this article on ORTEX.
Open GMRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
